Rational antihypertensive therapy: combined drugs in focus


Cite item

Full Text

Abstract

The article presents an algorithm for choosing the optimal drug for the treatment of arterial hypertension. The main groups of antihypertensive drugs with the characteristic of the mechanism of their action and possible side effects are described. The authors described in detail the combined antihypertensive drug Triplixam® (Servier Laboratory). The results of multicenter randomized trials of patients with arterial hypertension are presented. On the basis of clinical studies, the high efficacy of Triplixam® in the treatment of arterial hypertension has been proven.

About the authors

V. S Zadionchenko

A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation

Email: z7vladimir@bkl.ru
д-р мед. наук, проф. каф. поликлинической терапии; засл. деят. науки 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1

A. A Yalymov

A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation

канд. мед. наук, доц. каф. поликлинической терапии 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1

G. G Shekhyan

A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation

канд. мед. наук. доц. каф. поликлинической терапии 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1

A. M Shchikota

A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation

канд. мед. наук. доц. каф. поликлинической терапии 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1

N. A Ivanova

A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation

клин. ординатор каф. поликлинической терапии 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1

S. A Terpigorev

M.F.Vladimirskiy Moscow Regional Research Clinical Institute

Email: smith@yandex.ru
д-р мед. наук, проф., рук. отд-ния профпатологии и врачебно-трудовой экспертизы 129110, Russian Federation, Moscow, ul. Shchepkina, d. 61/2

T. G Kabanova

M.F.Vladimirskiy Moscow Regional Research Clinical Institute

Email: kabanova75@yandex.ru
канд. мед. наук, науч. сотр. отд-ния профпатологии и врачебно-трудовой экспертизы 129110, Russian Federation, Moscow, ul. Shchepkina, d. 61/2

A. M Nikishenkov

M.F.Vladimirskiy Moscow Regional Research Clinical Institute

мл. науч. сотр. отд-ния профпатологии и врачебно-трудовой экспертизы 129110, Russian Federation, Moscow, ul. Shchepkina, d. 61/2

References

  1. Задионченко В.С., Шехян Г.Г., Тимофеева Н.Ю. и др. Особенности комбинированной антигипертензивной терапии в современном лечении артериальной гипертензии. Рус. мед. журн. 2011; 19 (26): 1630-9.
  2. Карпов Ю.А. Периндоприл: клиническая эффективность у всех больных с сосудистым заболеванием или высоким его риском через вазопротекцию. Consilium Medicum. 2009; 11 (1): 51-5.
  3. Недогода С.В. Престариум А в лечении артериальной гипертензии и пациентов высокого риска: почему ему отдается предпочтение? Consilium Medicum. 2010; 12 (1): 45-9.
  4. Преображенский Д.В., Сидоренко Б.А., Романова Н.Е., Шатунова И.М. Клиническая фармакология основных классов антигипертензивных препаратов. Consilium Medicum. 2000; 2 (3): 99-127.
  5. Asmar R, London G, O'Rourke M. et al. Improvement in blood pressure, arterial stiffness and wave reflections with a very-low-dose peridopril/indapamide combination in hypertensive patients. A comparison with atenolol. Hypertension 2001; 38: 922-6.
  6. Horwitz L.D. et al. Comparison of amlodipine and long-acting diltiazem in the treatment of mild or moderate hypertension. Am J Hypertens 1997; 10 (11): 1263-9.
  7. Dahlof B, Sever P.S, Poulter N.R. et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895-906.
  8. Терещенко Н. EUROPA открывает новые горизонты применения ингибиторов АПФ. Consilium Medicum. 2003; 5 (11): 664-8.
  9. Dahlof B. The PICXEL study benefits of a low dose combination on left ventricular hypertrophy reduction. XIV European Meeting on Hypertension, Paris, 2004.
  10. PROGRESS Management Committee. Blood pressure lowering for the secondary prevention of stroke: rationale and design for PROGRESS (Perindopril Protection Against Recurrent Stroke Study). Hypertension 1996; 14 (Suppl.): 41-5.

Copyright (c) 2017 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies